Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
2007

Tumour Lysis Syndrome in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Imatinib

Sample size: 1 publication Evidence: low

Author Information

Author(s): Elizabeth M. Pinder, Gurprit S. S. Atwal, Abraham A. Ayantunde, Sarah Khan, Mike Sokal, Tom McCulloch, Simon L. Parsons

Primary Institution: Nottingham City Hospital

Hypothesis

This case report aims to describe the occurrence of tumour lysis syndrome (TLS) in a patient with metastatic gastrointestinal stromal tumour treated with imatinib.

Conclusion

The patient experienced tumour lysis syndrome as a direct consequence of imatinib treatment for gastrointestinal stromal tumour.

Supporting Evidence

  • The patient developed classic features of tumour lysis syndrome after starting imatinib.
  • Post-mortem examination revealed significant tumour cell kill consistent with the effects of imatinib.
  • The patient had multiple risk factors for TLS, including compromised renal function and bulky tumour.

Takeaway

This study talks about a man who got very sick after taking a medicine for his stomach cancer, which caused his body to react badly and led to serious health problems.

Methodology

Case report detailing the clinical course and post-mortem findings of a patient treated with imatinib.

Limitations

The case report is based on a single patient, limiting generalizability.

Participant Demographics

An 81-year-old man with a history of gastrointestinal stromal tumour and other comorbidities.

Digital Object Identifier (DOI)

10.1155/2007/82012

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication